NPPA Caps Trade Margins for 137 Non-Scheduled Anti-Cancer Drugs
- On October 17, 2026, the National Pharmaceutical Pricing Authority capped trade margins at 30% for 137 non-scheduled anti-cancer drugs in India to improve medicine affordability and expand patient access to cancer treatments.
- This intervention builds upon the success of a 2019 pilot program, extending the approach to a larger list of drugs recommended by an Expert Committee under the Directorate General of Health Services .
- The regulatory move is expected to reduce the Maximum Retail Price of these anti-cancer medicines by up to 70%, depending on existing pricing structures, aiming to alleviate the financial burden on patients.
- Manufacturers must report revised prices within seven days of the Gazette notification, with new rates effective from November 9 for all retailers and hospitals to implement.
- Consumers can verify updated costs through the Pharma Sahi Daam app and NPPA website, while State Drug Controllers will monitor compliance to ensure affordable access to treatments.
14 Articles
14 Articles
Devdiscourse
NPPA caps trade margins for 137 non-scheduled anti-cancer drugs
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has undertaken Trade Margin Rationalisation (TMR) of 137 identified non-scheduled anti-cancer drugs in public interest to address excessive trade margins, make cancer treatment more affordable, and improve access to anti-cancer medicines.
Govt notifies 30% cap on trade margins on 137 cancer drugs, new prices from November 9
The National Pharmaceutical Pricing Authority (NPPA) has decided to limit the profit margins that distributors, stockists and chemists can add to 137 cancer drugs. The move is aimed at reducing the prices patients pay for these medicines. The new prices are expected to take effect from November 9, 2026.
Govt caps trade margins on 137 anti-cancer drugs at 30%; revised prices from November 9 - The Tribune
The measure covers a range of expensive cancer medicines, including targeted therapies and immunotherapies such as pembrolizumab, nivolumab, osimertinib, palbociclib, ribociclib, abemaciclib, atezolizumab and bevacizumab
Coverage Details
Bias Distribution
- 78% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
